Published in Vaccine Weekly, November 6th, 2002
Anita R. Schnapp and colleagues at St. Louis University and Washington University in St. Louis, explained that they chose cruzipain for testing because it "is expressed by all developmental forms and strains of the parasite and stimulates potent humoral and cellular immune responses during infection in both humans and mice."
The investigators created a line of CD4+ T lymphocytes that were reactive to cruzipain and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly